Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
See All Experts
featured
Published in Oncology

Expert Opinion / Conference Coverage · June 17, 2015

ASCO 2015 Recap: Gastrointestinal Cancer—Part 2

Axel Grothey MD

 

 Save  Recommend
 Share

Additional Info

  1. Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer [published online March 12, 2015]. Science. DOI: 10.1126/science.aaa1348.
  2. Siena S, Sartore-Bianchi A, Lonardi S, et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015; Chicago, IL. Abstract 3508.

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Further Reading

Most Read This Week

Recently Updated